Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: In January 2020, the FDA granted approval of avapritinib under the brand name AYVAKIT for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. In September 2020, the European Commission granted conditional marketing authorization to AYVAKYT as a monotherapy for the treatment of adult patients with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. In June 2021, the FDA granted a subsequent approval for AYVAKIT, expanding the labeled indications to include adult patients with advanced SM, including aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia. In September 2020, the FDA granted accelerated approval to pralsetinib under the brand name GAVRETO for the treatment of adult patients with metastatic RET fusion-positive NSCLC as detected by an FDA approved test. In December 2020, the FDA granted a subsequent accelerated approval for GAVRETO, expanding the labeled indications to include adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). For the year ended December 31, 2021, our revenue mainly consisted of product sales of our drugs as well as collaboration revenue under our collaborations with Roche, CStone and Zai Lab. We recorded net product revenue Assistant:

  2. Assistant

    Positive: In January 2020, the FDA approved avapritinib under the brand name AYVAKIT for adults dealing with unresectable or metastatic GIST that contain a PDGFRA exon 18 mutation, such as PDGFRA D842V mutations. By September 2020, the European Commission gave AYVAKIT conditional marketing authorization as a standalone therapy for treating adult patients with unresectable or metastatic GIST showing the PDGFRA D842V mutation. The FDA extended its approval for AYVAKIT in June 2021 to encompass adult patients with advanced systemic mastocytosis, including aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia. In September 2020, GAVRETO (pralsetinib) received accelerated approval from the FDA for adult patients with metastatic RET fusion-positive non-small cell lung cancer as determined by a test approved by the FDA. In December 2020, GAVRETO's indications were broadened with another accelerated approval from the FDA to cover adult and pediatric patients aged 12 and above with advanced or metastatic RET-mutant medullary thyroid cancer needing systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer needing systemic therapy and who do not respond to radioactive iodine (where appropriate). Ending December 31, 2021, our revenue was primarily made up of product sales of our medications and collaboration revenue from our partnerships with Roche, CStone, and Zai Lab. We recorded net product revenue.

    Negative: In January 2020, the FDA denied approval of avapritinib, marketed as AYVAKIT, for adults with unresectable or metastatic GIST containing a PDGFRA exon 18 mutation, excluding PDGFRA D842V mutations. In September 2020, the European Commission rejected marketing authorization for AYVAKIT. In June 2021, the FDA declined further approval for AYVAKIT for any additional indications. In September 2020, the FDA did not approve pralsetinib, known as GAVRETO, for any treatment for adults. In December 2020, the FDA withdrew any provisional approvals for GAVRETO, limiting its use for any groups. Our revenue by December 31, 2021, barely included any product sales, nor did we gain from collaborations with Roche, CStone, or Zai Lab. We did not report any net product revenue.